RenovoRx to Participate in ROTH Capital Deep Dive Webinar on October 27, 2022 at 1:00 P.M. ET

Rhea-AI Summary

RenovoRx, Inc. (Nasdaq: RNXT) announced CEO Shaun Bagai will participate in a ROTH Capital webinar on October 27 at 1 p.m. ET. The discussion will focus on RenovoRx's mission to innovate oncology therapy through its RenovoTAMP treatment, which aims to improve quality of life and enhance survival for patients with difficult-to-treat cancers. Bagai will also review the ongoing Phase 3 TIGeR-PaC clinical trial, with its first results expected in Q4 2023. The public can register to attend and ask questions during the session.

LOS ALTOS, Calif.--(BUSINESS WIRE)-- RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP^®) therapy platform, today announced that the Company’s CEO, Shaun Bagai, will participate in a ROTH Capital Partners Deep Dive webinar on Thursday, October 27^th at 1 p.m. ET. To register for the event please visit RenovoRx Fireside Chat Registration.

During the webinar, Mr. Bagai will discuss the company’s mission to become a leading provider in oncology therapy by disrupting standard of care (intravenous systemic chemotherapy) treatment of difficult-to-treat cancers, and how its unique RenovoTAMP therapy platform offers an innovative approach to delivering targeted chemotherapy to tumors. The goals of the RenovoTAMP therapy platform are to improve quality of life for patients living with difficult-to-treat cancer by reducing the debilitating side effects typical of standard of care chemotherapy treatment and to extend patient survival. Additionally, Mr. Bagai will review the Company’s pivotal Phase 3 TIGeR-PaC clinical trial which has its first interim analysis targeted for reporting in the fourth quarter of this year. The webinar is open to the public and participants will have an opportunity to ask questions during the Q&A portion of the webinar.

ROTH Capital Deep Dive Webinar
Format: Webinar
Host: Scott Henry, CFA – Managing Director, Senior Research Analyst & Head of Pharmaceuticals Research and the Medical Technology sector at ROTH Capital Partners
Participant: Shaun Bagai, CEO
Date and Time: Thursday, October 27^th at 1:00 p.m. ET
Register: RenovoRx Fireside Chat Registration

For additional information please contact KCSA Strategic Communications by emailing RenovoRx@KCSA.com.

About RenovoRx, Inc.
RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP^®) therapy platform. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. RenovoRx’s lead product candidate, RenovoGem™, is a combination of gemcitabine and our patented delivery system, RenovoCath^®, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). RenovoGem is currently being studied in the Phase 3 TIGeR-PaC trial for the treatment of LAPC.

RenovoRx’s patent portfolio for its therapy platform and product candidates includes seven U.S. patents, one European patent and several additional patents pending in the US, EU and Asia. RenovoRx has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine for the treatment of both pancreatic cancer and bile duct cancer.

RenovoRx won the Drug Delivery Technology category of the Fierce Innovation Awards – Life Sciences Edition 2020 for its RenovoTAMP technology.

Learn more by visiting the RenovoRx website or following us on Facebook, LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221021005058/en/

Company Contact:

RenovoRx, Inc.

Shaun R. Bagai, CEO

James Ahlers, CFO



Investor Contact:

KCSA Strategic Communications

Valter Pinto or Jack Perkins

T: 212-896-1254

renovorx@kcsa.com

Source: RenovoRx, Inc.

FAQ

When is the RenovoRx webinar hosted by ROTH Capital?

The RenovoRx webinar will take place on October 27 at 1 p.m. ET.

What will Shaun Bagai discuss in the webinar?

Shaun Bagai will discuss RenovoRx's oncology therapy innovations and the Phase 3 TIGeR-PaC clinical trial.

What is RenovoTAMP therapy?

RenovoTAMP is a proprietary therapy platform aimed at delivering targeted chemotherapy to tumors, improving patient quality of life.

What is the focus of the Phase 3 TIGeR-PaC trial?

The TIGeR-PaC trial focuses on treating unresectable locally advanced pancreatic cancer using RenovoRx's lead product candidate, RenovoGem.

How can I register for the RenovoRx webinar?

You can register for the webinar by visiting the ROTH Capital Partners registration link provided in the press release.

What is the purpose of the RenovoRx webinar?

The webinar aims to inform the public about RenovoRx's therapeutic advancements and to provide a Q&A session with CEO Shaun Bagai.